20
Participants
Start Date
February 14, 2019
Primary Completion Date
April 1, 2022
Study Completion Date
June 6, 2022
abaloparatide
In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days.
bevacizumab
In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
University of Rochester, Rochester
University of Rochester
OTHER